Gérard Jaouen graduated from the University of Rennes (France) in 1973. He spent the year 1973-74 at Cambridge working with Pr. the Lord (Jack) Lewis. Dr. Jaouen was appointed Director of Research in 1976 and became Professor at the University of Paris (ENSCP) in 1982, where in 1984 he founded a CNRS Associated Laboratory. In 1979 Dr. Jaouen decided to focus on bioorganometallic chemistry.

Professor Jaouen is the editor of 3 books, the author of 440 papers, and has been granted 16 patents. His achievements in bioorganometallic chemistry have been recognized by several international awards including the von Humboldt Gay-Lussac Prize (Berlin, Munich), the RSC Centenary Medal, the AIC Pioneer Award (Boston), the Bioorganometallic Award (Zurich), and several named lectures (Dublin, Montreal). He is a knight of the Légion d’Honneur (2006), is an elected fellow of the European Academy of Sciences and a member of the Academia Europaea (2012). 

Sergio Roman-Roman, Phd, is Head of translational research at Curie Institute, Paris. He started his career in 1987 as researcher at Gustave-Roussy Institute, before to move in 1992 to Roussel-Uclaf and Hoechst-Marion-Roussel

Being 6 years later head of cellular & molecular biology lab at Aventis Pharma, he collaborated in 2002 to the launch of Proskelia Pharmaceuticals. He started in 2007 at Curie Institute as head of partnerships. 

Professor in Chemistry at University of Angers.

She is also member of the MINT lab (Biomimetics Micro & Nanomedecines).

She leads the nanoparticules formulation activities with 2 PhD candidates financed by Feroscan.

Dr. Armand has been Managing Director of Gustave-Roussy Institute’s clinical department from 2000 to 2006, then he has been appointed Managing Director of the Claudius Regaud Institute in Toulouse from 2007 to 2012. The European Society for Medical Oncology (ESMO) has bestowed him the ESMO Award 2008. 

Research Director, CNRS. He worked with Pr. Jaouen, Dr. Pigeon on the development of the ferrocifen family. 

He is co-author of the patents for which Feroscan has exclusive rigths.

He is the PSL representant.

After having worked on the international scientific collaboration and financing aspects at Cyprus Institute, he started and developed the new Innovation and Entrepreunship Division at Ecole polytechnique. He joined Paris Sciences & Lettres at the same position in 2016.

Bruno holds a PhD in Physics from ENS Ulm/Paris VI.

From Investment Banker to Biotech risk taker, Franck is active in Biotechnologies & Cancer therapies as investor/business developer.

He took the helm of Feroscan in july 2018.

He is CEO of Evonik Advanced Botanicals.

He was the first CEO of Feroscan.

He has a PhD in Cellular & molecular Biology from Imperial College London.

She is Professor-Assistant at MINT Lab, University of Angers.

She managed with Pr. Passirani, the nanomedicines activities. 

She is PhD candidate working for Feroscan on the nanoparticules applications.

Topic: Nanoparticules, chargées en ferrocifènes, pour le traitement du cancer

He is Doctor in Pharmacy.

He is PhD candidate in Nanoparticules applied to medicines for Feroscan.

He is working with Pr. Jaouen, Dr. Top and Dr. Pigeon on the chemical part of the ferrocifens.

Mar. 2013-June 2015 Postdoctoral researcher of Dr Anne Vessières-Jaouen group, working with Dr Top and Prof. Jaouen, Laboratoire Charles Friedel (UMR 7223), Chimie ParisTech.

July 2011-Mar. 2013 Assistant Professor of Prof. Ya-qiu Long group, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica.

2006-2011 Ph.D. Thesis in Medicinal Chemistry at Prof. Ya-qiu Long group, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica.

July-Oct. 2010 Exchange Ph.D. student in Medicinal Chemistry and Chemical Biology at Prof. dr. Robert M.J. Liskamp group, Utrecht Institute for Pharmaceutical Sciences, Utrecht University.